Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in ...

A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.

Oblimersen sodium (Genasense™) is an antisense oligodeoxynucleotide specific for the antiapoptotic protein Bcl-2, which could enhance the sensitivity of leukemic cells to chemotherapy in this ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug.

Initially touted as an innovative by GlobalData’s analysts, Amylyx’s antisense therapy Relyvrio failed to achieve its endpoints in a Phase III study (NCT05021536) for ALS. The company formally ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

our antisense therapy could become a first- and best-in-class treatment option for patients with wet AMD and/or DME,” she added. ISTH0036 may offer a true alternative to current standard of care ...

In a phase 3 trial, the biotech linked the antisense molecule to an 81% drop in the monthly rate of swelling attacks. Intellia is betting there is a market for a therapy with a similar level of ...

Discover six exosome therapy companies developing these tiny extracellular vesicles to treat an array of diseases.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

In a study led by researchers at the NUS Yong Loo Lin School of Medicine, extracellular vesicles loaded with customizable ...

In phase II and phase III, there are several compounds targeting tau, especially monoclonal antibodies (such as E2814, ...